Commentary: “Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease” by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519

Detalles Bibliográficos
Autores principales: Alma, Harma, de Jong, Corina, Kocks, Janwillem, van der Molen, Thys
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280745/
https://www.ncbi.nlm.nih.gov/pubmed/32581793
http://dx.doi.org/10.3389/fphar.2020.00827
_version_ 1783543777536770048
author Alma, Harma
de Jong, Corina
Kocks, Janwillem
van der Molen, Thys
author_facet Alma, Harma
de Jong, Corina
Kocks, Janwillem
van der Molen, Thys
author_sort Alma, Harma
collection PubMed
description
format Online
Article
Text
id pubmed-7280745
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-72807452020-06-23 Commentary: “Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease” by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519 Alma, Harma de Jong, Corina Kocks, Janwillem van der Molen, Thys Front Pharmacol Pharmacology Frontiers Media S.A. 2020-06-02 /pmc/articles/PMC7280745/ /pubmed/32581793 http://dx.doi.org/10.3389/fphar.2020.00827 Text en Copyright © 2020 Alma, de Jong, Kocks and van der Molen http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Alma, Harma
de Jong, Corina
Kocks, Janwillem
van der Molen, Thys
Commentary: “Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease” by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519
title Commentary: “Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease” by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519
title_full Commentary: “Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease” by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519
title_fullStr Commentary: “Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease” by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519
title_full_unstemmed Commentary: “Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease” by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519
title_short Commentary: “Healthcare Professionals’ Preferred Efficacy Endpoints and Minimal Clinically Important Differences in the Assessment of New Medicines for Chronic Obstructive Pulmonary Disease” by Dankers M et al. in Frontiers in Pharmacology 2020; 10: 1519
title_sort commentary: “healthcare professionals’ preferred efficacy endpoints and minimal clinically important differences in the assessment of new medicines for chronic obstructive pulmonary disease” by dankers m et al. in frontiers in pharmacology 2020; 10: 1519
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280745/
https://www.ncbi.nlm.nih.gov/pubmed/32581793
http://dx.doi.org/10.3389/fphar.2020.00827
work_keys_str_mv AT almaharma commentaryhealthcareprofessionalspreferredefficacyendpointsandminimalclinicallyimportantdifferencesintheassessmentofnewmedicinesforchronicobstructivepulmonarydiseasebydankersmetalinfrontiersinpharmacology2020101519
AT dejongcorina commentaryhealthcareprofessionalspreferredefficacyendpointsandminimalclinicallyimportantdifferencesintheassessmentofnewmedicinesforchronicobstructivepulmonarydiseasebydankersmetalinfrontiersinpharmacology2020101519
AT kocksjanwillem commentaryhealthcareprofessionalspreferredefficacyendpointsandminimalclinicallyimportantdifferencesintheassessmentofnewmedicinesforchronicobstructivepulmonarydiseasebydankersmetalinfrontiersinpharmacology2020101519
AT vandermolenthys commentaryhealthcareprofessionalspreferredefficacyendpointsandminimalclinicallyimportantdifferencesintheassessmentofnewmedicinesforchronicobstructivepulmonarydiseasebydankersmetalinfrontiersinpharmacology2020101519

Ejemplares similares